Chimeric antigen receptor T-cell therapy for multiple myeloma.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 20 08 2019
accepted: 15 01 2020
pubmed: 26 1 2020
medline: 9 9 2020
entrez: 26 1 2020
Statut: ppublish

Résumé

Chimeric antigen receptor (CAR) T cell therapy, an immunotherapy using gene-modified T cells, has recently made a big success. CAR T cells targeting CD19 is highly effective against B cell malignancies. Next good target for CAR T therapy is multiple myeloma. B cell maturation antigen has been proved to be a good target for CAR T cell therapy in early-phase clinical trials. We are also developing CAR T cells targeting a protein conformation that is preferentially detected in myeloma cells. In this review, I will summarize the state of art in the field of CAR T cell therapy against myeloma, and also present our effort to develop a new CAR T cell therapy.

Identifiants

pubmed: 31981097
doi: 10.1007/s12185-020-02827-8
pii: 10.1007/s12185-020-02827-8
doi:

Substances chimiques

Antigens, CD19 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

530-534

Références

Int J Hematol. 2013 Mar;97(3):306-12
pubmed: 23420183
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830874
Sci Transl Med. 2019 Mar 27;11(485):
pubmed: 30918115
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Cytometry B Clin Cytom. 2016 Jan;90(1):26-30
pubmed: 25907102
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Nat Med. 2017 Dec;23(12):1436-1443
pubmed: 29106400
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
Br J Haematol. 2013 Dec;163(5):551-64
pubmed: 24111932
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Mol Cancer Ther. 2019 Sep;18(9):1555-1564
pubmed: 31270154

Auteurs

Naoki Hosen (N)

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH